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Background: Candidiasis is a major cause of human morbidity and mortality. Human
uterine cervical stem cells conditioned medium (hUCESC-CM) is obtained from stromal
stem cells of the cervical transformation zone, which are in permanent contact with
a wide array of potential vaginal pathogens. In previous reports we have found that
hUCESC-CM has antitumor and antibacterial potential. Since Candida is the most
prevalent yeast in the human vagina, it seems plausible that hUCESC-CM might also
show activity against it.
Methods: In a preliminary step, to evaluate if hUCESC-CM showed any activity at all
on Candida growth, in vitro activities of hUCESC-CM against fluconazole-susceptible
reference strains of Candida albicans, Candida glabrata, Candida krusei, and Candida
parapsilosis were studied with a microdilution method on RPMI 1640, using the
BioScreen C microbiological incubator. Each measurement was repeated five times. The
same methodology was used subsequently on fluconazole-susceptible and fluconazole-
resistant Candida isolates from blood and vagina of those species corresponding to the
reference strains of Candida against which activity had been detected in the previous
study. Moreover, two fluconazole-resistant clinical isolates of Candida auris from blood
and urine were also included.
Findings: In vitro inhibitory activity of hUCESC-CM ranged from 57.5 to 96.6%
growth-reduction against fluconazole-susceptible reference strains of Candida albicans,
Candida glabrata, and Candida parapsilosis. hUCESC-CM also reduced the growth of
all fluconazole-susceptible tested vaginal isolates by more than 50%. For fluconazole-
resistant isolates, growth-reduction was higher than 67% for Candida albicans,
regardless of its origin (vagina or blood). The isolate of Candida auris from urine with a
MIC > 128 µ/ml for fluconazole was also significantly inhibited. However, hUCESC-CM
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was almost inactive against any of the fluconazole-resistant blood isolates of Candida
glabrata, Candida parapsilosis, and Candida auris tested.
Interpretation: This is the first report about the growth-inhibiting properties of
conditioned medium from human stromal stem cells against different species of
Candida. Antifungal activity of stromal stem cells depends on their site of origin, being
most effective against Candida species most prevalent at that particular location. If
confirmed in further studies, these findings might result in a completely new therapeutic
approach against superficial and invasive candidiasis.
Keywords: antifungal activity, human uterine cervical stem cells, secretome, Candida, Candida albicans, Candida
glabrata, Candida parapsilosis
INTRODUCTION
Invasive candidiasis is a major cause of human morbidity and
mortality (Quindós, 2014). Moreover, mucosal candidiasis, such
as oral and vaginal candidiasis, are very common diseases: more
than 75% of all women suffer from vulvovaginal candidiasis
at least once in their life and most denture carriers suffer
from Candida-associated lesions (Singh et al., 2014; Aguin and
Sobel, 2015). In 5–10% of women, vaginal candidiasis recurs
several times (Weissenbacher et al., 2009). Candida albicans is
the prevalent etiology of invasive candidiasis. However, other
species, such as Candida glabrata, Candida parapsilosis, or
Candida krusei, are the etiology of an increasing number of
candidiasis (Pemán et al., 2012; Puig-Asensio et al., 2014) as
well as Candida auris that more recently has globally emerged
as a nosocomial pathogen (Chowdhary et al., 2018; Quindós
et al., 2018). These emergent species of Candida frequently
show a reduced susceptibility to common antifungal drugs used
for treating these diseases, such as fluconazole, voriconazole or
the echinocandins, anidulafungin, caspofungin or micafungin
(Arendrup and Patterson, 2017; Chowdhary et al., 2018).
Treatment of candidiasis represents a significant unsolved clinical
challenge. New antifungal compounds are required to meet the
great clinical challenge posed by invasive and therapy-resistant
superficial candidiasis (McCarthy and Walsh, 2017).
We have recently identified and characterized a new strain
of human cervical stromal stem cells, which possess antitumoral
effects (Eiró et al., 2014). Moreover, the secretome of these cells
also exerts antibiotic, anti-inflammatory and reepithelization-
enhancing effects (Bermúdez et al., 2015). Our hypothesis is
that they constitute a key element in the defense mechanism
of the human uterine transformation zone against its biological
threats. Indeed, their secretome, contained in their conditioned
culture medium (hUCESC-CM), inhibits proliferation above a
certain threshold and induces apoptosis of highly proliferating
tumor cells (Eiró et al., 2014). At the same time, it enhances
reepithelization, and thus proliferation below the safety limit,
and shows antibiotic and anti-inflammatory properties in a
corneal ulcer animal model (Bermúdez et al., 2015). All this
exactly mimics the situation of the cervical transformation zone,
which, as has been outlined above, is in a constant process of
controlled hyperproliferation and reepithelization (Mitra et al.,
2015), within a proinflammatory environment in which bacteria
and other microorganisms abound. Our working theory is that
stromal stem cells from that particular area have developed, along
evolution, some site-specific properties, directed at protecting the
remaining cellular environment from external damage through a
paracrine mechanism modulating intrinsic defense mechanisms
(Schneider et al., 2016). It is already an accepted fact that,
although the defining feature of stem cells is that they are
undifferentiated and can be redifferentiated into virtually any
kind of mature cell, depending on their site of origin, their
features are not exactly the same (Vizoso et al., 2017). One of
the potentially threatening microorganisms that colonizes the
vagina is Candida. Usually its growth is kept under control in the
homeostatic environment of the vaginal microbiota (Döderlein
flora), comprising a number of other microorganisms, most
notably lactobacilli. Indeed, the bacterial concentration in the
vagina is the highest in the human body, with the exception
of the colon. However, when this physiological equilibrium is
disrupted, e.g., in the case of antibiotic treatment, yeasts may
grow out of control and produce clinical symptoms, and very
often huge discomfort to the patient. In up to 20% of instances,
the condition will become chronic, despite the restoration of the
normal vaginal microbiota. With this in mind, we have tested
the potential homeostasis-restoring and antifungal properties of
the hUCESC-CM, in order to verify if its antibiotic potential,
already demonstrated in the case of bacteria (Eiró et al., 2014),
also extends to the next most frequent agent present in the vaginal
medium, namely Candida.
MATERIALS AND METHODS
The study was approved by the Ethics Committee for Regional
Clinical Research of Principado de Asturias (Spain, Ethics
reference number 100/13) and by the Ethics Committee of
the Universidad del País Vasco/Euskal Herriko Unibertsitatea
(UPV/EHU, Bilbao, Spain, CEIAB Ethics reference number
M30_2015_248).
Microorganisms
In a first step, four commercially available reference strains
(Candida albicans ATCC 90028, Candida glabrata ATCC 90030,
Candida krusei ATCC 6258, and Candida parapsilosis ATCC
22019) were tested. Following the results obtained with these
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reference strains, we repeated the experiments on clinical isolates
from actual patients conserved at the microorganism bank
of Laboratorio de Micología Médica at UPV/EHU (Medical
Mycology Laboratory of the University of the Basque Country
at Leioa, Bilbao) and on two clinical isolates of Candida
auris obtained from patients with candidemia from Hospital
Universitario y Politécnico La Fe (Valencia, Spain) (Ruiz-Gaitán
et al., 2018).
Compounds
hUCESC-CM was obtained as previously described (Eiró et al.,
2014). The medium was maintained lyophilized until its use. The
lyophilized powder was resuspended in 2 ml of double distilled
water prior to its use, which mimics the original concentration of
the conditioned culture medium of hUCESCs.
In vitro Antifungal Activities hUCESC-CM
Antimicrobial in vitro activities against Candida were tested as
follows: yeast inocula were prepared by growing the isolates
on Sabouraud dextrose agar plates for 24 h at 37 ◦C and
adjusting to a final concentration between 1 × 103 and 5 × 103
cells/ml in RPMI 1640 medium buffered to pH 7.0 with 0.165 M
morpholinepropanesulfonic acid. A 100 µl suspension of each
Candida strain and 100 µl of the conditioned media assayed (at
a final 1:2 dilution) were added to each well of the dedicated
100 well-microtiter plate supplied with the BioScreen System
(BioScreen C MBR; LabSystems, Helsinki, Finland). Culture
medium and yeast-free controls were included in triplicate in
each assay. The first control included 100 µl hUCESC-CM
and 100 µl double-distilled water, and the second one, 100 µl
inoculum in RPMI and 100 µl double distilled water. The plates
were cultivated at 37◦C for 24–72 h in a computer-controlled
microbiological incubator (BioScreen C MBR; LabSystems,
Helsinki, Finland). Antifungal activities of the compounds were
studied by means of the optical density measured every hour in
the incubator. Each experiment was repeated five times on two
consecutive days.
Yeast Staining for Microscopy
Yeast viability and morphology of three strains, Candida glabrata
ATCC 90030, Candida albicans UPV-15-178 and Candida
albicans UPV-15-154 were checked after 24 h incubation.
One microliter of FUN-1 R©dye from the kit LIVE/DEAD Yeast
Viability Kit (Thermo Fisher Scientific S.L., United States) was
added both to treated and untreated samples and incubated in the
dark for 30 min. The effect of hUCESC-CM on plasma membrane
integrity and metabolic function of Candida cells was visualized
using an Olympus Fluoview FV500 confocal microscope.
Cytokine Expression in hUCESC-CM
We studied the cytokine content of our study medium by means
of a human cytokine antibody array as previously described
(Eiró et al., 2014).
Statistical Analysis
The growth reduction percentage at each time interval was
calculated relative to the growth control. Comparisons between
group values were performed by means of Student’s t-test,
p < 0.05 being regarded as statistically significant. Comparisons
of protein expression in media between groups were performed
by means of one-way ANOVA and Bonferroni post hoc.
RESULTS
All the results are summarized in Table 1 and the OD readings for
the first 24 h, the period during which the effect of hUCESC-CM
was most marked, are represented in Figures 1, 2.
In the preliminary study on Candida reference strains,
antifungal activity, recorded as a reduction of cell growth
compared to the control after 24 h of culture at 37◦C, was
excellent against Candida glabrata (96.6%), Candida parapsilosis
(72.9%), and Candida albicans (57.5%). However, there was
no clear activity against Candida krusei, whose growth seemed
even to be slightly enhanced by the presence of hUCESC-
CM, although not significantly so (Figure 1 and Table 1).
The antifungal activity against Candida glabrata of hUCESC-
CM was particularly striking (Supplementary Figure S1).
When repeating the study on clinical isolates from our
microorganism collection, the antifungal activity of hUCESC-
CM was equally effective against all fluconazole-susceptible
tested isolates (Candida albicans, Candida glabrata, and Candida
parapsilosis) which had been obtained from the vagina of patients.
However, for those obtained from the blood of patients, and
for fluconazole-resistant isolates, the situation was different: the
response was still excellent for Candida albicans, regardless of
its origin (vagina or blood) and comparable to that of the
corresponding fluconazole-susceptible isolates. However, none
of the fluconazole-resistant isolates of Candida glabrata and
Candida parapsilosis obtained from the blood of patients showed
any response (Figure 2 and Table 1).
Therefore, among the 17 isolates tested, 13 presented growth
inhibition in the presence of hUCESC-CM, and in 11 of them, it
was higher than 50%. These 11 isolates corresponded to (i) the
five Candida albicans isolates tested, from blood and vagina (ii)
three of the five Candida glabrata isolates tested, two from vagina
and one from blood (iii) two of the four Candida parapsilosis
isolates from vagina and skin, and (iv) the Candida auris isolate
from urine. Moreover, the growth of the five vaginal Candida
isolates was inhibited in presence of hUCESC-CM (from 51.6 to
81.9%). Moreover, when a 1:4 dilution was tested with three of
the clinical isolates,Candida aurisUPV 17–285,Candida albicans
UPV 15–147 and Candida albicans UPV 15–178, a decrease in
growth inhibition of Candida was observed (data not shown).
Furthermore, we carried out an exploratory re-analysis on
four of the previously tested Candida albicans and Candida
glabrata strains at pH 4.5, the upper limit of physiological
vaginal pH. This was prompted by the findings from Danby
et al. (2012), who reported different activities of 11 tested
antifungal agents against Candida albicans and Candida glabrata
depending on the pH of the culture medium. We found
that the activity of hUCESC-CM was largely unchanged
against the two susceptible strains of Candida albicans and
Candida glabrata (48.5% vs. 57.5% and 73.0% vs. 73.1% growth
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TABLE 1 | Twenty four hours in vitro activity of human stromal uterine cervical stem cell conditioned medium (hUCESCs-CM) against Candida.
Candida strains Origin Fluconazole susceptibility Growth inhibition (%) p-value
C. albicans ATCC 90028 Blood Susceptible 57.5 <0.05
C. glabrata ATCC 90030 Blood Susceptible 96.6 <0.05
C. krusei ATCC 6258 Sputum Susceptible -11.9 0.28
C. parapsilosis ATCC MYA 4646 Skin Susceptible 72.9 <0.05
C. albicans UPV-15-178 Blood Susceptible 88.6 <0.05
C. albicans UPV-15-154 Blood Resistant 67.1 <0.05
C. albicans UPV-12-117 Vagina Susceptible 51.6 <0.05
C. albicans UPV-15-147 Vagina Resistant 79.4 <0.05
C. glabrata UPV-03-282 Blood Susceptible 24.8 <0.05
C. glabrata UPV-07-200 Blood Resistant 0 –
C. glabrata UPV-15-141 Vagina Susceptible 73.1 <0.05
C. glabrata UPV-15-202 Vagina Resistant 81.9 <0.05
C. parapsilosis UPV-07-073 Blood Susceptible 0 –
C. parapsilosis UPV-07-058 Blood Resistant 0 –
C. parapsilosis UPV-12-241 Vagina Susceptible 60.5 <0.05
C. auris UPV-17-257 Blood Resistant 18.3 0.3
C. auris UPV-17-285 Urine Resistant 56 <0.05
inhibition, respectively), and was even enhanced in the only
fluconazole-resistant vaginal Candida albicans strain tested
(97.4% vs. 79.4%). On the other hand, the inhibitory effect was
markedly diminished against the fluconazole-resistant Candida
glabrata strain tested (21.5% vs. 81.9% growth reduction)
(Supplementary Figure S2).
The effect of hUCESC-CM was easily visualized with the
viability assay performed with confocal microscopy (Figure 3).
After 24 h of incubation, the yeasts treated with hUCESC-CM
appeared green, and thus were not able to convert the
yellow–green fluorescent intracellular staining into red-orange,
indicating damage in their plasma membrane integrity and
metabolic function. However, no variation in cell morphology
was observed.
There were no Candida albicans germ tubes or hyphae in
those wells incubated with hUCESC-CM. However, there were
no germ tubes or hyphae present in the wells used as controls
(less than 10% Candida albicans cells showed any elongation).
Some inhibition of Candida albicans adhesion and biofilm
development was observed in wells with hUCESC-CM. However,
these observations are not included, as adhesion and biofilm
development or the action of hUCESC-CM against Candida
FIGURE 1 | Antifungal activities of conditioned culture medium (hUCESC-CM) against the reference strains Candida albicans ATCC 90028 (A), Candida glabrata
ATCC 90030 (B), Candida krusei ATCC 6258 (C), and Candida parapsilosis ATCC 22019 (D). Growth curves for the first 24 h of culture without huCESCs-CM ()
and in presence of huCESCs-CM ().
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FIGURE 2 | Antifungal activities of conditioned culture medium (hUCESC-CM) against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida
albicans and Candida glabrata both from blood (UPV-15-178 and UPV-03-282) and vagina (UPV-15-147 and UPV-15-202). Growth curves for the first 24 h of
culture without huCESCs-CM () and in presence of huCESCs-CM ().
FIGURE 3 | Candida glabrata ATCC 90030 viability by Laser Confocal Microscope. Cells stained with FUN-1 R©dye from the kit LIVE/DEAD Yeast Viability Kit after
24 h of incubation without conditioned culture medium (hUCESC-CM) (A) and in presence of hUCESC-CM (B).
preformed biofilms have not been tested in an assay specific for
evaluating these actions.
The study of cytokine expression in our study and control
media showed that several cytokines with known antifungal
activity (IL-6, IL-8, IL-17, IP-10, CXCL-16, CCL-5, and CCL-6)
were expressed at high levels in comparison to those shown by the
culture medium itself (the negative control). We also introduced
an additional control, namely adipose stem cells (Figure 4), in
order to test whether the high cytokine levels expressed by our
strain of stem cells (hUCESCs) are peculiar to it, or rather a
general feature of stromal stem cells.
DISCUSSION
To the best of our knowledge, this preliminary report is
the first one about the antifungal properties of human stem
cell conditioned medium, in this particular case hUCESC-
CM. Stem cells are the reservoir from which any other
cell type can develop. Therefore, it seems plausible from an
evolutionary point of view that they have developed intrinsic
defense mechanisms against any potential threats from the
environment. Furthermore, it appears that some of those defense
mechanisms are more or less developed, depending on the
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FIGURE 4 | IL-6, IL-8, CCL-5, IP-10, CXC-16, IL-17, and CXCL6 protein expression in culture medium (white bars), in hUCESC-CM (gray bars) and in human
adipose stem cells (hASC-CM) (black bars) after 48 h of culture. Error bars represent mean ± SD of signal intensity value as detected in RayBio human cytokine
antibody array (∗p < 0.05).
particular site of origin of every particular stem cell population
(Schneider et al., 2016). This seems to be corroborated in our
study by the finding that the antifungal activity of huCESC-
CM was highest against those strains obtained from the vaginal
medium, which is the environment in permanent contact
with the source of huCESCs, the human cervical transition
zone. Conversely, this seems also to indicate that yeasts may
modify their phenotype and develop different mechanisms
of resistance, depending on the environment in which they
thrive, a notion that might have important implications in
the clinical setting, when choosing a treatment. In fact, none
of the fluconazole-resistant isolates different from Candida
albicans obtained from the blood of patients was affected in
its growth by the incubation with huCESC-CM. On the other
hand, we found that the fluconazole-resistant isolate of Candida
albicans (UPV-15-154) obtained from a patient with systemic
candidiasis did respond significantly to hUCESC-CM. This is
a highly encouraging finding, since systemic candidiasis is a
potentially life-threatening condition, for which the outcome
of conventional treatments is often disappointing (Arendrup
and Patterson, 2017). Although vaginal candidiasis is not life
threatening, on the other hand, it is nevertheless an extremely
disturbing condition for the patient, affecting her quality of
life. Recurrent vaginal candidiasis, furthermore, is often devoid
of a satisfactory treatment. hUCESC-CM showed a significant
growth-inhibiting potential against all tested vaginal Candida
isolates, including against both fluconazole-resistant Candida
albicans isolates tested. Furthermore, this effect seems to be
preserved under pH conditions similar to those found in
the vagina, according to our very preliminary sub-analysis, as
described in the “Results.” If confirmed in further studies, which
are mandatory, this would corroborate the previous findings
reported by Danby et al. (2012) in their fundamental study on
the variation of antifungal agent activity against Candida albicans
andCandida glabrata under different pH conditions. Considering
the known influence of hormones, particularly estrogens, on the
vaginal medium and Candida growth, it would be also important
to study the activity of huCESC-CM against Candida in the
presence of steroidal hormones mimicking their physiological
vaginal levels in premenopausal and postmenopausal women.
In a previous report from our group, we have shown that
hUCESC-CM has antibiotic and anti-inflammatory properties
(Bermúdez et al., 2015). From the results of the current study,
these defense mechanisms against external threats seem to extend
also to Candida, and in the case of hUCESC-CM, particularly
against those strains most prevalent in the vagina, such as
Candida albicans and Candida glabrata. All in all, this may
indicate that the transformation zone of the uterine cervix must
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have developed along evolution a very robust defense mechanism
against its multiple biological threats enumerated above.
The mediators of this pleiotropic defense mechanism are
largely unknown, although we begin to have some clues. In
our previous report about the antitumoral effect of hUCESC-
CM conditioned medium (Eiró et al., 2014), we studied its
cytokine content by means of a human cytokine antibody array.
Several of the cytokines expressed at high levels have known
antifungal effects, such as IL-6, IL-8, IL-17, IP-10, CXCL-16, CCL-
5, and CCL-6. In particular, IL-17 is essential for mucocutaneous
immunity against Candida albicans (Ling et al., 2015). Although
the standard mechanism of action of cytokines implies immune
cell signaling, there is also evidence that cytokines exert a direct
effect on fungal cells. Indeed, Zelante et al. (2012) have reported
that IL-17 directly binds to Candida albicans, hereby impairing
its growth independently from the presence of immune system
cells. Moreover Li et al. (2013) have reported that IL-17 directly
blocks proliferation of other eukaryotic cells, such as neural stem
cells, resulting in significantly reduced numbers of astrocytes and
oligodendrocyte precursor cells. On a purely speculative level,
a similar effect could take place against cells of Candida. Thus,
in addition to its proinflammatory role through activation of
the immune system, IL-17 may have direct effects on Candida
cell proliferation. As can be seen from Figure 4, IL-17 levels in
hUCESC-CM were several times higher than those found either
in the negative control (the culture medium) or, interestingly,
in another widely studied strain of stem cells which we used as
an additional control in this experiment, namely adipose stem
cells, indicating that this high level of interleukins with antifungal
properties is not a general feature of stromal stem cells, but a
specific one of our strain of hUCESCs, most probably due to
evolutionary pressure induced by the threat posed by Candida
in the vagina toward the extremely fragile transformation zone
of the cervix (Schneider et al., 2016). It is at present completely
unknown if the other cytokines identified by us and expressed at
high levels in hUCESC-CM also have a direct antifungal action,
like IL-17, besides the “classical” one involving host immune
cells, but it might well be that at least some of them do. Besides,
they certainly induce an immune antifungal response in the
living tissue surrounding the transformation zone of the cervix
under physiological conditions in the living organism. Therefore,
speculatively, hUCESC-CM, used as a local antifungal treatment
in the vagina, might have a dual action: the direct one shown in
this study, plus the “classical” one through induction of the host
immune cells.
Fluconazole is a first choice antifungal drug in the treatment
of mucosal candidiasis, such as Candida vulvovaginitis (single
oral dose) and one of the first choices in the targeted treatment
of invasive candidiasis caused by those species of Candida
usually susceptible to fluconazole, such as Candida albicans and
Candida parapsilosis. However, superficial and deep candidiasis
caused by species less susceptible of even resistant to fluconazole,
such as Candida krusei, Candida glabrata or Candida auris,
are becoming more frequent (Arendrup and Patterson, 2017;
Chowdhary et al., 2018). Some of these species may be resistant
to echinocandins and even amphotericin B. In these important
medical challenges, new therapeutic alternatives are increasingly
necessary, with either new drugs, combining two or more of the
existing ones, finding new indications for old drugs or developing
new biological therapies that allow action to be taken on virulence
factors, cell differentiation or Candida metabolism (McCarthy
and Walsh, 2017). In the current study, preliminary results of one
of these latter approaches have been reported with the intention
of contributing new ideas and data to the essential debate on
the treatment of those infections, such as candidiasis, caused by
pathogens resistant to conventional drugs and treatments.
CONCLUSION
We have reported for the first time the growth-inhibiting
properties of human cervical stromal stem cells′ conditioned
medium (hUCESC-CM) against different species of Candida. If
confirmed in further studies, these findings might result in a
completely new therapeutic approach against candidiasis.
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